Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lacking "Mediator," EC Tightens Pharmacovigilance Proposals

This article was originally published in The Pink Sheet Daily

Executive Summary

European Commission's surprise update of the pharmacovigilance rules is included in its review of the information to patients legislation, but industry's biggest concern may be the failure to address the role of social media.

You may also be interested in...



EU SCOPE Project Will Harmonize Pharmacovigilance, Benefit Industry

The EU SCOPE pharmacovigilance project will harmonize practices across the 28 member states, thereby cutting the administrative and cost burden for pharmaceutical manufacturers.

Risk Management Professional Society Would Aim To Improve REMS Performance

Initial focus of volunteer industry group of pharmaceutical risk managers is drafting publications which assess the effectiveness of Risk Evaluation and Mitigation Strategies.

EMA Moves To Reassure Europe Over Combined Contraceptives

EMA says there is currently no cause for concern, amid increasing claims in Europe’s media that combined contraceptives can cause blood clots.

Related Content

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel